NCT02712047 - A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2016

Primary Completion Date

February 21, 2017

Study Completion Date

February 21, 2017

Conditions

Asthma

Interventions

DRUG

Fluticasone furoate (FF) (100 mcg)

First blister strip contains FF blended with lactose, 100 mcg per blister

DRUG

Vilanterol (VI) (25 mcg)

Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister

DRUG

Placebo

Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate

Trial Locations (1)

6021

GSK Investigational Site, Newtown, Wellington